Theriva Biologics Inc. (TOVX) Live Share Price, Invest From India

Theriva Biologics Inc. Stock Performance

as on April 15, 2026 at 6:59 am IST

Day's High
$0.24
Day's Price Range
$0.27
$0.24
12.50%
Upside
52 Week's Low
52 Week's High
$0.16
52-Week Price Range
$1.50
$0.24
32.17%
Downside
525.00%
Upside

Theriva Biologics Inc. share price movements today

Previous Close: $0.25
Open: $0.26
Volume: 2.7M
Day's Low - High: $0.24 - $0.27
52 Week Low - High: $0.16 - $1.50

Theriva Biologics Inc. Historical Returns

1 Month Return: + 44.46 %
3 Month Return: + 26.11 %
1 Year Return: -82.54 %
3 Year Return: -98.61 %
5 Year Return: 0 %

Theriva Biologics Inc. Stock Fundamentals & Key Indicators

Check Theriva Biologics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$10.6M

EPS (TTM)

-0.2

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-14.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-137.82%

Theriva Biologics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Theriva Biologics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Theriva Biologics Inc.	BUY	$10.6M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$42.7B	140.76%	138.84	8.45%
Vertex Pharmaceuticals Inc	BUY	$111.0B	102.67%	28.5	32.94%
BeiGene, Ltd.	NA	$35.6B	NA	124.86	5.37%
Regeneron Pharmaceuticals Inc	BUY	$79.2B	55.14%	18.05	31.41%

Stock Returns calculator for Theriva Biologics Inc. Stock including INR - Dollar returns

The Theriva Biologics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Theriva Biologics Inc. investment value today

Current value as on today

₹17,905

Returns

-₹82,095

(-82.1%)

Returns from Theriva Biologics Inc. Stock

-₹83,448 (-83.45%)

Dollar Impact

₹1,353 (+1.35%)

Analyst Recommendation on Theriva Biologics Inc. Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Theriva Biologics Inc.. Average target price of $2.5

Theriva Biologics Inc. Share Price Target

Get share price movements and forecasts by analysts on Theriva Biologics Inc..

What analysts predicted

90.4%UPSIDE

Target Price

$2.5

Current Price

$0.24

Analyzed by

8 Analysts

Target

$2.50

Theriva Biologics Inc. target price $2.5, a slight upside of 90.4% compared to current price of $0.24. According to 8 analysts rating.

Theriva Biologics Inc. Stock’s Investor Sentiment and Interest

Search interest for Theriva Biologics Inc. Stock has increased by 112% in the last 30 days, reflecting an upward trend in search activity.

Time period: March 16, 2026 to April 15, 2026

Change:112% versus previous 30 day period

Theriva Biologics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	0	-	-	-	0	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	-	0
Operating Income	-4	-5	-5	-8	-7	-4	-4	-13	-4	-2
EBITDA	-5	-5	-5	-4	-5	-4	-4	-13	-4	6
Interest Expense	-	0	-	-	-	0	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-3	-5	-5	-8	-7	-4	-4	-13	-4	-1
Income Tax Expense	0	0	0	-	-	0	-	-	-	1
Net Income	-3	-5	-5	-8	-7	-4	-4	-13	-4	-3
Net Profit Margin	0.00%	-723.61%	0.00%	0.00%	0.00%	-2887.66%	0.00%	0.00%	0.00%	0.00%

Theriva Biologics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0
Operating Income	-17	-15	-10	-14	-21	-21	-26	-15
EBITDA	-17	-15	-9	-14	-19	-21	-19	-14
Interest Expense	-	-	-	0	0	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-13	-15	-10	-14	-21	-19	-25	-23
Income Tax Expense	-4	0	0	0	-1	-1	-	1
Net Income	-13	-15	-10	-14	-19	-18	-25	-25
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Theriva Biologics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-5	-5	-8	-7	-4	-4	-13	-4	-1
Operating Cash Flow	-6	-4	-3	-3	-4	-4	-4	-4	-2
Investing Cash Flow	0	-	0	-	-	-	0	0	-
Financing Cash Flow	-1	-	1	3	0	3	6	0	8
Change in Cash	-7	-4	-1	0	-4	-1	2	-4	5

Theriva Biologics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-15	-13	-15	-10	-14	-19	-18	-25	-23
Operating Cash Flow	-20	-17	-13	-12	-12	-19	-18	-16	-16
Investing Cash Flow	0	0	0	0	0	-4	0	0	0
Financing Cash Flow	18	29	3	3	74	-1	0	5	18
Change in Cash	-1	11	-13	-8	61	-25	-18	-11	1

Insights on Theriva Biologics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, TOVX stock has moved up by 44.5%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 161.9%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 38.7% return, outperforming this stock by 121.2%

About Theriva Biologics Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Organisation	Theriva Biologics Inc.
Headquarters	9605 Medical Center Drive, Rockville, MD, United States, 20850
Industry	Biotechnology
CEO	Mr. Steven A. Shallcross CPA
E-voting on shares	Click here to vote

Key Management of Theriva Biologics Inc.

Name	Title
Mr. Steven A. Shallcross CPA	CEO, CFO, Treasurer, Corporate Secretary & Director
Dr. Vince Wacher Ph.D.	Head of Product & Corporate Development
Dr. Ramon Alemany Ph.D.	Senior Vice President of Discovery

FAQs

What is Theriva Biologics Inc. share price today?

Theriva Biologics Inc. share price today is $0.24 as on April 15, 2026 at 1:29 am IST at the close of the market. Theriva Biologics Inc. share today touched a day high of $0.27 and a low of $0.24.

What is the 52 week high and 52 week low for Theriva Biologics Inc. share?

Theriva Biologics Inc. share touched a 52 week high of $1.5 on April 25, 2025 and a 52 week low of $0.16 on February 23, 2026. Theriva Biologics Inc. stock price today i.e. April 15, 2026 at 1:29 am IST is closed at $0.24,which is 84.00% down from its 52 week high and 47.42% up from its 52 week low.

What is Theriva Biologics Inc.'s market capitalisation today?

Theriva Biologics Inc. market capitalisation is $0.00T as on April 15, 2026 at 1:29 am IST.

How to invest in Theriva Biologics Inc. Stock (TOVX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Theriva Biologics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Theriva Biologics Inc. Shares that will get you 6.2500 shares as per Theriva Biologics Inc. share price of $0.24 per share as on April 15, 2026 at 1:29 am IST.

What is the minimum amount required to buy Theriva Biologics Inc. Stock (TOVX) from India?

Indian investors can start investing in Theriva Biologics Inc. (TOVX) shares with as little as ₹93.082 or $1 (as of April 15, 2026 at 3:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹930.82 in Theriva Biologics Inc. stock (as per the Rupee-Dollar exchange rate as on April 15, 2026 at 3:39 am IST). Based on Theriva Biologics Inc. share’s latest price of $0.24 as on April 15, 2026 at 1:29 am IST, you will get 41.6667 shares of Theriva Biologics Inc.. Learn more about fractional shares .